Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC Sponsored ADR ( (HLN) ) has issued an announcement.
On August 27, 2025, Haleon PLC announced the purchase and cancellation of 2,975,063 ordinary shares as part of its ongoing share buyback program, initially announced on July 31, 2025. This transaction, completed on August 26, 2025, is part of Haleon’s strategy to optimize its capital structure and enhance shareholder value, potentially impacting its market position and stakeholder interests.
The most recent analyst rating on (HLN) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
Haleon PLC’s overall stock score reflects strong financial performance and efficient cash flow generation, offset by mixed technical indicators and moderate valuation. The earnings call provided a balanced view of strengths in international markets and challenges in North America. The company’s ability to navigate these challenges and capitalize on growth opportunities will be crucial for future performance.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company’s product portfolio includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health, featuring well-known brands like Advil, Centrum, and Sensodyne.
Average Trading Volume: 12,510,945
Technical Sentiment Signal: Buy
Current Market Cap: $43.21B
For detailed information about HLN stock, go to TipRanks’ Stock Analysis page.